Science translational medicine · 2025
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Giorgi Marco, Park So Hyun, Castoreno Adam, Cao Mingming, Hurley Ayrea, Saxena Lavanya, Chuecos Marcel A, Walkey Christopher J, Doerfler Alexandria M, Furgurson Mia N, Ljungberg M Cecilia, Patel Kalyani R, Hyde Sarah, Chickering Tyler, Lefebvre Stephanie, Wassarman Kelly, Miller Patrick, Qin June, Schlegel Mark K, Zlatev Ivan, Han Jun, Beeton Christine, Li Rich Gang, Kim Jong, Martin James F, Bissig Karl-Dimiter, Jadhav Vasant, Bao Gang, Lagor William R
Аннотация
Homology-directed repair (HDR)-based genome editing is an approach that could permanently correct a broad range of genetic diseases. However, its utility is limited by inefficient and imprecise DNA repair mechanisms in terminally differentiated tissues. Here, we tested Repair Drive, a platform technology for selectively expanding HDR-corrected hepatocytes in adult mice in vivo. Repair Drive involves transient conditioning of the liver by knocking down an essential gene, fumarylacetoacetate hydrolase (Fah), and delivering an untargetable version of the essential gene in cis with a therapeutic transgene. We show that Repair Drive increased the percentage of correctly targeted hepatocytes in healthy wild-type mice up to 25%, which resulted in a fivefold increased expression of a therapeutic transgene, human factor IX (FIX). Repair Drive was well tolerated and did not induce toxicity or tumorigenesis during a 1-year follow-up. This approach may broaden the range of liver diseases that can be treated with somatic genome editing.